Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29678
Title: Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
Authors: SCHEINBERG, MortonPINEDA, CarlosCASTANEDA-HERNANDEZ, GilbertoZARBA, Juan JoseDAMIAO, AdersonARANTES JR., Luiz H.JACOBS, Ira
Citation: MABS, v.10, n.6, p.827-842, 2018
Abstract: Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the opportunity to commercialize highly similar versions, known as biosimilars. Biosimilars are approved by regulatory agencies via an independent pathway that requires extensive head-to-head comparison with the originator product. Biosimilars have the potential to provide savings to healthcare systems and expand patient access to biologics. In Latin American countries, regulatory frameworks for biosimilar approval have been introduced in recent years, and biosimilars of monoclonal antibody and fusion protein therapies are now emerging. However, the situation in this region is complicated by the presence of non-comparable biotherapeutics (also known as intended copies), which have not been rigorously compared with the originator product. We review the considerations for clinicians in Latin American countries, focusing on monoclonal antibody biosimilars relevant to oncology, rheumatology, gastroenterology, and dermatology.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC


Files in This Item:
File Description SizeFormat 
art_SCHEINBERG_Biosimilars_in_oncology_and_inflammatory_diseases_current_and_2018.PDF
  Restricted Access
publishedVersion (English)1.73 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.